Antitrust may not be drugmakers’ top policy concern

Ben Remaly

27 January 2020

Credit: Shutterstock/James Andrews1

As pharmaceutical companies lobby against bipartisan efforts to curb prescription drug prices, there may be room for competition-related bills to be signed into law.

Subscribe to Global Competition Review

Subscribe and start reading now

Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.

Subscribe now

Already have access? Login below

Ben Remaly

View full biography

Author | Senior news reporter, Global Competition Review

[email protected]

Get unlimited access to all Global Competition Review content